Rachel W. Linnemann

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Claire Keating, Lael M. Yonker, F. Vermeulen et al. · The Lancet Respiratory Medicine · 2025 · 89 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one<i>F508del</i>allele: 144-week interim results from a 192-week open-label extension study

Cori Daines, Elizabeth Tullis, Stefano Costa et al. · European Respiratory Journal · 2023 · 88 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

The Fecal Microbiota Profile and Bronchiolitis in Infants

Kohei Hasegawa, Rachel W. Linnemann, Jonathan M. Mansbach et al. · PEDIATRICS · 2016 · 81 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Nasal Airway Microbiota Profile and Severe Bronchiolitis in Infants

Kohei Hasegawa, Rachel W. Linnemann, Jonathan M. Mansbach et al. · The Pediatric Infectious Disease Journal · 2016 · 72 citations

Life Sciences, Microbiology, Pediatrics +17